Phase III data met the standards but still faced sell-offs! Citi maintains Moderna (MRNA.US) "Sell" rating, with an $80 target price suggesting over 60% downside potential.
智通财经2026/10/26 13:42Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
According to Golden Finance APP, Citi has released a research report maintaining a "Sell" rating and an $80 target price for Moderna (MRNA.US). The bank pointed out that an investor call held by Moderna during the European Society for Medical Oncology (ESMO) conference further reinforced management's confidence in its personalized oncology therapy platform, but did not substantially change Citi's views on the company's commercialization limitations and valuation disconnect.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
